Cambridge, Massachusetts, April 27, 2026, 15:04 EDT
Intellia Therapeutics on Monday reported its experimental CRISPR gene-editing therapy led to a significant reduction in swelling attacks in a late-stage hereditary angioedema study. The company has started a rolling submission for U.S. approval of the drug, called lonvoguran ziclumeran, or lonvo-z. Designed as an outpatient infusion, lonvo-z targets a rare disorder that triggers severe swelling in areas like the face, airway, abdomen, and limbs.
Timing comes into play here: Intellia has shifted the program from simply reporting clinical data to lining up for regulatory review. A biologics license application—BLA—is what companies file to seek U.S. approval for a biologic drug. “In vivo” CRISPR refers to editing genes directly inside a patient, instead of changing cells in the lab and then putting them back. SEC
The HAELO study enrolled 80 patients: 52 got lonvo-z, while the other 28 received placebo. Just one 50 mg infusion cut attacks by 87% compared to placebo during the six-month efficacy window. Patients on lonvo-z averaged 0.26 attacks per month, versus 2.10 for those on placebo, according to a securities filing.
Lonvo-z didn’t just hit its main target—the drug also met important secondary endpoints. Over the six-month stretch, 62% of patients given lonvo-z stayed both attack-free and off therapy, a sharp contrast to the 11% seen with placebo.
Intellia says hereditary angioedema, or HAE, impacts roughly one in 50,000 individuals. Current preventive treatments often mean frequent injections or taking pills every day, but even then, patients can experience breakthrough attacks, according to the company.
Intellia says its lonvo-z therapy targets the KLKB1 gene, aiming to knock down kallikrein and bradykinin—two proteins linked to swelling. John Leonard, who serves as Intellia’s president and CEO, described the findings as a “profound milestone.” Aleena Banerji, a professor at Harvard Medical School and trial investigator, said the treatment could become an “appealing option” if it wins approval. Intellia Therapeutics
Safety questions aren’t going away. According to the filing, patients on the lonvo-z arm mostly experienced mild or moderate treatment-emergent adverse events, with no serious ones reported before the cutoff. There was just one case of Grade 2 ALT elevation—a liver enzyme issue—which cleared up in a week.
Shares wavered. Reuters had noted a roughly 3% jump for Intellia earlier on the data, but more recent figures showed the stock slipping 0.9% to $13.51, after hitting an intraday peak at $18.29.
The product would be stepping into a market that already offers patients alternatives. Ionis Pharmaceuticals’ Dawnzera and Takeda Pharmaceutical’s Takhzyro are among existing HAE treatments. Intellia CFO Edward Dulac told analysts that lonvo-z will probably come with a price tag above current therapies, but also cautioned, per Reuters, that setting it too high risks payer resistance.
Still, that update hasn’t cleared the biggest overhang. Steve Seedhouse at Cantor calls lonvo-z “probably a niche product,” flagging a potential warning label because of a fatal liver toxicity case in another Intellia CRISPR program. The FDA halted those late-stage studies last year, later lifting the hold on one. Reuters
Intellia is aiming to wrap up its BLA submission in the back half of 2026, targeting a potential U.S. launch in early 2027 if the FDA gives the green light. According to the company, its FDA regenerative-medicine designation allows for rolling submission and might pave the way for more direct agency oversight.
All eyes now turn to the European Academy of Allergy and Clinical Immunology Congress in Istanbul this June, where more data are expected. The focus, for the moment, moves past whether the edit succeeds in late-stage testing. Now, the real question is whether regulators, payers, and patients will sign off on a one-off, permanent solution for a disease that’s typically handled with repeat dosing.
